Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A recent publication inNature Medicine in which Seyedmehdi Shojaee, Markus Müschen and colleagues show that deletion of the tumour suppressor PTENin pre-B cell acute lymphoblastic leukaemia (pre-B ALL) cells results in cell death.
Enriquez-Navaset al. show that an evolution-based adaptive treatment strategy is more effective than standard therapy for controlling tumour growth in orthotopic xenograft mouse models of breast cancer.
Two studies inScience report that co-deletion of MTAP — which is common in CDKN2A-deleted cancers — is not a silent passenger event but renders cells sensitive to inhibition of protein arginine methyltransferase 5 (PRMT5), a dependency that could be therapeutically targeted in MTAP-deleted cancers.
Hata, Niederstet al. present data suggesting that genetic resistance to the epidermal growth factor receptor (EGFR) inhibitor gefitinib can develop either through selection of clones carrying a pre-existing resistance mutation, or through the eventual de novodevelopment of a resistance mutation in cells that survive initial therapy.
Roybalet al. have designed a system in which two tumour antigens are required to effectively induce T cell activation through chimeric antigen receptors, which in principle could improve the efficacy and safety of T cell therapies.